Comparative Pharmacology
Head-to-head clinical analysis: MYDRIAFAIR versus PAREDRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYDRIAFAIR versus PAREDRINE.
MYDRIAFAIR vs PAREDRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antimuscarinic; blocks acetylcholine at muscarinic receptors in iris sphincter and ciliary muscle, causing mydriasis and cycloplegia.
Paredrine (hydroxyamphetamine) is a sympathomimetic amine that acts as an indirect-acting adrenergic agonist, displacing norepinephrine from presynaptic nerve terminals and inhibiting its reuptake, leading to activation of alpha- and beta-adrenergic receptors.
Administered as one drop of phenylephrine 2.5% and tropicamide 1% ophthalmic solution in each eye 15-20 minutes prior to examination; may repeat once in 5-10 minutes if needed.
5-10 mg intramuscularly (IM) or subcutaneously (SC) every 30-60 minutes as needed; intravenous (IV) dose: 2-5 mg every 5-10 minutes, not to exceed 50 mg total.
None Documented
None Documented
Terminal elimination half-life is 1.5 hours; prolonged to 3-4 hours in renal impairment.
Terminal elimination half-life is 12-15 hours; may be prolonged in renal impairment.
Renal: 80% as unchanged drug and metabolites; fecal: 20% via biliary excretion.
Renal (approximately 80% as unchanged drug and metabolites); biliary/fecal (minor, <10%).
Category C
Category C
Mydriatic
Mydriatic